Cytomyx has recently extended its portfolio to include a catalogue of novel high-value products - important tools for any research lab involved in early stage drug discovery
Cytomyx, the well known research services provider, has recently extended its portfolio to include a catalogue of novel high-value products - important tools for any research lab involved in early stage drug discovery.
This first Cytomyx catalogue has now been launched and is available in the UK and Ireland from Cambridge BioScience.
Cytomyx is a fast growing, innovative company that is leading the field in protein based tools for early stage drug discovery, specialising in products and services for ion channel, GPCR, PDE and kinase related research.
The G-protein coupled receptor (GPCR) family of genes represents one of the largest families of drug targets in the human genome.
It is estimated that some 30% of drugs currently on the market are targeting GPCR function.
A wide range of GPCR antibodies is now available from Cytomyx.
Kinases represent almost 2% of all expressed genes and regulate a large variety of essential cellular events, including cell cycle, proliferation, adhesion, motility and apoptosis. Cytomyx has launched a new product line of over 70 kinase specific antibodies reactive to human and, in many cases, murine and rat enzymes as well.
